ClinicalTrials.gg
Active, not recruitingNCT03975647Updated Jul 23, 2026Results posted

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

A Phase 3 interventional study of tucatinib and placebo in HER2-positive Breast Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 490 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.

Enrollment
5th of 31
466 · median 41
Started
2019
with 1 other
Phase 3
3 of 31
none open now
Primary completion
2023-06
later than 0 of 18 live
Registered
9th of 31
by date
Lead sponsor
4 of 31
Seagen, a wholly owned subsidiary of Pfizer

Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 3, reaches primary completion later than 0 of the 18 other live ones, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tucatinib

tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing tucatinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery.

Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer.

Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills or placebo pills two times every day. Patients will get T-DM1 injections from the study site staff on the first day of every cycle.

Read the detailed description

This study is designed to evaluate the efficacy and safety of tucatinib in combination with T-DM1 in participants with unresectable locally-advanced or metastatic HER2+ breast cancer who have had prior treatment with a taxane and trastuzumab in any setting. Prior pertuzumab treatment is permitted, but not required. Participants will be randomized in a 1:1 manner to receive 21-day cycles of either tucatinib or placebo in combination with T-DM1.

While on study treatment, participants will be assessed for progression every 6 weeks for the first 24 weeks, and every 9 weeks thereafter, irrespective of dose holds or interruptions. Study treatment will continue until unacceptable toxicity, disease progression, withdrawal of consent, or study closure. After completion of study treatment and after occurrence of disease progression, participants in both arms of the study will continue to be followed for survival until study closure or withdrawal of consent.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • Seattle Genetics
  • Seagen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed + breast carcinoma as determined by a sponsor-designated central laboratory

    • History of prior treatment with a taxane and trastuzumab in any setting, separately or in combination
    • Have progression of unresectable locally advanced/ breast cancer after last systemic therapy, or be intolerant of last systemic therapy
    • Measurable or non- assessable by v1.1
    • performance status score of 0 or 1
    • CNS Inclusion - Based on screening contrast brain magnetic resonance imaging (MRI), participants must have at least one of the following:

      (a) No evidence of

      (b) Untreated brain metastases not needing immediate local therapy

      (c) Previously treated brain metastases

      1. Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy, provided that there is no clinical indication for immediate re-treatment with local therapy
      2. Participants treated with CNS local therapy for newly identified lesions or previously treated and progressing lesions may be eligible to enroll if all of the following criteria are met:

        (i) Time since SRS is at least 7 days prior to first dose of study treatment, time since WBRT is at least 14 days prior to first dose, or time since surgical resection is at least 28 days.

        (ii) Other sites of evaluable disease are present

      3. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions

Exclusion criteria

  • Prior treatment with tucatinib, afatinib, trastuzumab deruxtecan (DS-8201a), or any other anti-, anti-EGFR, or HER2 TKI agent. Prior treatment with lapatinib or neratinib within 12 months of starting study treatment (except in cases where they were given for ≤21 days and was discontinued for reasons other than disease progression or severe toxicity). Prior treatment with pyrotinib for recurrent of mBC (except in cases where pyrotinib was given for ≤21 days and was discontinued for reasons other than disease progression or severe toxicity).

    • CNS Exclusion - Based on screening contrast brain magnetic resonance imaging (MRI), participants must not have any of the following:

      1. Any untreated brain lesions >2 cm in size
      2. Ongoing use of for control of symptoms of at a total daily dose of >2 mg of dexamethasone (or equivalent).
      3. Any brain lesion thought to require immediate local therapy
      4. Known or concurrent as documented by the investigator
      5. Poorly controlled generalized or complex partial seizures
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
466 participants (actual)

Study arms

  • Experimental
    Tucatinib + T-DM1

    Tucatinib + T-DM1

    Drug: tucatinib · Drug: T-DM1

  • Active comparator
    Placebo + T-DM1

    Placebo + T-DM1

    Drug: placebo · Drug: T-DM1

Interventions

  • 300mg given twice per day by mouth (orally)

    Also known as: ONT-380

  • Drugplacebo

    Given twice per day orally

  • DrugT-DM1

    3.6 mg/kg given into the vein (IV; intravenously) every 21 days

    Also known as: Kadcyla

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment

    PFS as per investigator was defined as the time from the date of randomization to the investigator assessment of disease progression (PD) as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimiter (mm). Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment.

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact).

    Time frame: Up to approximately 5 years

  2. Progression-Free Survival as Per RECIST v1.1 in Participants With Brain Metastases at Baseline Based on Investigator Assessment

    PFS as per investigator was defined as the time from the date of randomization to the investigator assessment of PD as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. PFS was analyzed in participants with presence or history of brain metastases.

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 45 months)

  3. Objective Response Rate (ORR) as Per RECIST v1.1 Based on Investigator Assessment

    ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (\<)10 mm. PR: a greater than equal (\>=) 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. ORR by investigator assessment is based on investigator response assessments. Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD or death, whichever occurred first (maximum up to 43 months)

  4. Overall Survival in Participants With Brain Metastases at Baseline

    OS was defined as the time from randomization to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). OS was analyzed in participants with presence or history of brain metastases.

    Time frame: Up to approximately 5 years

  5. Progression-Free Survival as Per RECIST v1.1 Determined by Blinded Independent Committee Review (BICR)

    PFS as per BICR was defined as the time from the date of randomization to the centrally-reviewed documented PD as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documented progression of PD or death at the time of analysis were censored at the date of the last tumor assessment.

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)

  6. Progression-Free Survival in Participants With Brain Metastases at Baseline as Per RECIST v1.1 Determined by BICR

    PFS as per BICR was defined as the time from the date of randomization to the centrally-reviewed documented PD as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS was analyzed in participants with presence or history of brain metastases.

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)

  7. Objective Response Rate as Per RECIST v1.1 Determined by BICR

    ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR per BICR is based on BICR response assessments.

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)

  8. Duration of Response (DOR) as Per RECIST v1.1 Based on Investigator Assessment

    DOR was defined as the time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD as per RECIST v1.1 PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. DOR per investigator was based on investigator response assessments.

    Time frame: Up to approximately 5 years

  9. Duration of Response as Per RECIST v1.1 by BICR

    DOR was defined as the time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD as per RECIST v1.1 PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. DOR per BICR was based on BICR response assessments.

    Time frame: Up to approximately 5 years

  10. Clinical Benefit Rate (CBR) Per RECIST v1.1 Based on Investigator Assessment

    CBR was defined as the percentage of participants with stable disease (SD) or non-CR or non-PD \>= 6 months or best response of CR or PR according to RECIST v1.1. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CBR was based on investigator assessment.

    Time frame: Up to approximately 5 years

  11. Clinical Benefit Rate as Per RECIST v1.1 by BICR

    CBR was defined as the percentage of participants with SD or non-CR or non-PD \>= 6 months or best response of CR or PR according to RECIST v1.1. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CBR per BICR is based on BICR response assessments.

    Time frame: Up to approximately 5 years

  12. Number of Participants With Treatment Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE was defined as AE that is newly occurred or worsened after the start of study treatment.

    Time frame: From start of treatment up to 30 days after the last study treatment (approximately 43 months)

07

Results

Posted Jul 30, 2024

Participant flow

Participants diagnosed with locally advanced (LA) or metastatic human epidermal growth factor receptor 2 positive (HER2+) breast cancer who received prior treatment with a taxane and trastuzumab in any setting, were evaluated for efficacy and safety of tucatinib in combination with ado-trastuzumab emtansine (T-DM1) in this study.

Participant flow — Overall Study
MilestoneTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Started231235
Intent-to-treat (itt) analysis set228235
Completed151159
Not completed8076
Withdrew: Death7163
Withdrew: Lost to follow-up22
Withdrew: Subject withdrawal of consent711

Outcome measures

PrimaryProgression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment

PFS as per investigator was defined as the time from the date of randomization to the investigator assessment of disease progression (PD) as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimiter (mm). Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment.

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment
MonthsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment9.5 (7.4 to 10.9)7.4 (5.6 to 8.1)
Statistical analysis
  • Tucatinib+ Ado-trastuzumab Emtansine vs Placebo+ Ado-trastuzumab Emtansine · Log Rank · p = 0.0163 · Hazard ratio (hr): 0.759 · 95% CI 0.607 to 0.950HR was calculated from Cox proportional hazards model. (line of treatment for metastatic: first versus \[vs\] other; hormone receptor status: negative vs positive; presence or history of brain metastases: yes vs no; ECOG status: 0,1 at randomization.
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact).

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryProgression-Free Survival as Per RECIST v1.1 in Participants With Brain Metastases at Baseline Based on Investigator Assessment

PFS as per investigator was defined as the time from the date of randomization to the investigator assessment of PD as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. PFS was analyzed in participants with presence or history of brain metastases.

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 45 months)
Reported as:
Median · Months
Progression-Free Survival as Per RECIST v1.1 in Participants With Brain Metastases at Baseline Based on Investigator Assessment
MonthsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Progression-Free Survival as Per RECIST v1.1 in Participants With Brain Metastases at Baseline Based on Investigator Assessment7.8 (6.7 to 10.0)5.7 (4.6 to 7.5)
Statistical analysis
  • Tucatinib+ Ado-trastuzumab Emtansine vs Placebo+ Ado-trastuzumab Emtansine · Log Rank · p = 0.0078 · Hazard ratio (hr): 0.639 · 95% CI 0.459 to 0.891HR was calculated from Cox proportional hazards model. (line of treatment for metastatic: first versus \[vs\] other; hormone receptor status: negative vs positive; presence or history of brain metastases: yes vs no; ECOG status: 0,1 at randomization.
SecondaryObjective Response Rate (ORR) as Per RECIST v1.1 Based on Investigator Assessment

ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (\<)10 mm. PR: a greater than equal (\>=) 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. ORR by investigator assessment is based on investigator response assessments. Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD or death, whichever occurred first (maximum up to 43 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Per RECIST v1.1 Based on Investigator Assessment
Percentage of participantsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Objective Response Rate (ORR) as Per RECIST v1.1 Based on Investigator Assessment42.0 (34.9 to 49.4)36.1 (29.3 to 43.4)
Statistical analysis
  • Tucatinib+ Ado-trastuzumab Emtansine vs Placebo+ Ado-trastuzumab Emtansine · Cochran-Mantel-Haenszel · p = 0.2055
SecondaryOverall Survival in Participants With Brain Metastases at Baseline

OS was defined as the time from randomization to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). OS was analyzed in participants with presence or history of brain metastases.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryProgression-Free Survival as Per RECIST v1.1 Determined by Blinded Independent Committee Review (BICR)

PFS as per BICR was defined as the time from the date of randomization to the centrally-reviewed documented PD as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documented progression of PD or death at the time of analysis were censored at the date of the last tumor assessment.

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)
Reported as:
Median · Months
Progression-Free Survival as Per RECIST v1.1 Determined by Blinded Independent Committee Review (BICR)
MonthsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Progression-Free Survival as Per RECIST v1.1 Determined by Blinded Independent Committee Review (BICR)9.6 (7.5 to 10.9)7.4 (5.5 to 8.4)
SecondaryProgression-Free Survival in Participants With Brain Metastases at Baseline as Per RECIST v1.1 Determined by BICR

PFS as per BICR was defined as the time from the date of randomization to the centrally-reviewed documented PD as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS was analyzed in participants with presence or history of brain metastases.

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)
Reported as:
Median · Months
Progression-Free Survival in Participants With Brain Metastases at Baseline as Per RECIST v1.1 Determined by BICR
MonthsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Progression-Free Survival in Participants With Brain Metastases at Baseline as Per RECIST v1.1 Determined by BICR7.8 (6.9 to 10.0)5.5 (4.2 to 7.4)
SecondaryObjective Response Rate as Per RECIST v1.1 Determined by BICR

ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR per BICR is based on BICR response assessments.

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)
Reported as:
Number · Percentage of participants
Objective Response Rate as Per RECIST v1.1 Determined by BICR
Percentage of participantsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Objective Response Rate as Per RECIST v1.1 Determined by BICR47.3 (39.8 to 54.8)41.1 (33.9 to 48.5)
SecondaryDuration of Response (DOR) as Per RECIST v1.1 Based on Investigator Assessment

DOR was defined as the time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD as per RECIST v1.1 PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. DOR per investigator was based on investigator response assessments.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryDuration of Response as Per RECIST v1.1 by BICR

DOR was defined as the time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD as per RECIST v1.1 PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. DOR per BICR was based on BICR response assessments.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate (CBR) Per RECIST v1.1 Based on Investigator Assessment

CBR was defined as the percentage of participants with stable disease (SD) or non-CR or non-PD \>= 6 months or best response of CR or PR according to RECIST v1.1. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CBR was based on investigator assessment.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate as Per RECIST v1.1 by BICR

CBR was defined as the percentage of participants with SD or non-CR or non-PD \>= 6 months or best response of CR or PR according to RECIST v1.1. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CBR per BICR is based on BICR response assessments.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE was defined as AE that is newly occurred or worsened after the start of study treatment.

Time frame:
From start of treatment up to 30 days after the last study treatment (approximately 43 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
ParticipantsTucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab Emtansine
Number of Participants With Treatment Emergent Adverse Events (AEs)230233

Adverse events

Collected over From start of treatment up to 30 days after the last study treatment (approximately 43 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo+ Ado-trastuzumab Emtansine63/233 (27%)52/233 (22.3%)227/233 (97.4%)
Tucatinib+ Ado-trastuzumab Emtansine71/231 (30.7%)70/231 (30.3%)230/231 (99.6%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventPlacebo+ Ado-trastuzumab EmtansineTucatinib+ Ado-trastuzumab Emtansine
SepsisInfections and infestations4/2334/231
PneumoniaInfections and infestations4/2331/231
ThrombocytopeniaBlood and lymphatic system disorders1/2333/231
DiarrhoeaGastrointestinal disorders0/2333/231
NauseaGastrointestinal disorders2/2333/231
VomitingGastrointestinal disorders3/2333/231
PyrexiaGeneral disorders2/2333/231
Drug-induced liver injuryHepatobiliary disorders0/2333/231
SeizureNervous system disorders3/2333/231
Acute kidney injuryRenal and urinary disorders2/2333/231
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPlacebo+ Ado-trastuzumab EmtansineTucatinib+ Ado-trastuzumab Emtansine
NauseaGastrointestinal disorders113/233151/231
DiarrhoeaGastrointestinal disorders62/233131/231
FatigueGeneral disorders85/233113/231
HeadacheNervous system disorders90/23383/231
VomitingGastrointestinal disorders39/23385/231
Aspartate aminotransferase increasedInvestigations45/23383/231
EpistaxisRespiratory, thoracic and mediastinal disorders46/23379/231
Alanine aminotransferase increasedInvestigations40/23378/231
Decreased appetiteMetabolism and nutrition disorders53/23378/231
ConstipationGastrointestinal disorders77/23361/231

Baseline characteristics

The ITT analysis set included all participants who were randomized on or before the date of last patient in (LPI) in the global study.

Age, Continuous
Age, Continuous(Years)Tucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab EmtansineTotal
Mean53.8 ± 11.452.9 ± 10.953.4 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Tucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab EmtansineTotal
Female226235461
Male202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab EmtansineTotal
Hispanic or Latino81321
Not Hispanic or Latino171163334
Unknown or Not Reported4959108
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tucatinib+ Ado-trastuzumab EmtansinePlacebo+ Ado-trastuzumab EmtansineTotal
American Indian or Alaska Native011
Asian6665131
Native Hawaiian or Other Pacific Islander303
Black or African American11819
White101102203
More than one race516
Unknown or Not Reported4258100
08

Study locations

490 sites

Showing the first 100 of 490 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hurvitz SA, Loi S, O'Shaughnessy J, Okines AFC, Tolaney SM, Sohn J, Saura C, Zhu X, Cameron D, Bachelot T, Hamilton E, Curigliano G, Wolff AC, Harbeck N, Masuda N, Vahdat L, Zaman K, Valdes-Albini F, Block M, Pluard T, Tan TJ, Gawryletz C, Chan A, Bedard PL, Yerushalmi R, Xu B, Schmitt M, Xie D, Borges VF; HER2CLIMB-02 study investigators. Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. Ann Oncol. 2026 Mar;37(3):341-352. doi: 10.1016/j.annonc.2025.11.005. Epub 2025 Nov 17. PubMed 41260264 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jun 2023, 44 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 44 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2019
First posted
Jun 5, 2019
StartActual
Oct 2, 2019
Primary completionActual
Jun 29, 2023
CompletionEst.
Mar 10, 2029
Results first posted
Jul 30, 2024
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03975647
Responsible party
Sponsor
First posted
Jun 5, 2019
Start date
Oct 2, 2019
Primary completion
Jun 29, 2023
Completion
Mar 10, 2029 (estimated)
Results posted
Jul 30, 2024
Last update
Jul 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion